Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 12Recruiting 11Active not recruiting 5Terminated 3Withdrawn 2Unknown 1No longer available 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 11Gastrointestinal 10Genitourinary 6Other solid neoplasm 5Gynecologic 3Breast 3Tumor-Agnostic 2CNS 2Sarcoma 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Neoplasm Metastasis 1Carcinoma, Squamous Cell 1

Interventions

Magnetic Resonance Spectroscopy 5Cisplatin 5Gemcitabine 4trametinib 2repotrectinib 2pembrolizumab 2enzalutamide 2atezolizumab 2Surveys and Questionnaires 2SS1(dsFv)PE38 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Paclitaxel 2Nivolumab 2Interviews as Topic 2Docetaxel 2Cetuximab 2Carboplatin 2vinflunine 1veliparib 1vadimezan 1toripalimab 1talazoparib 1sintilimab 1reolysin 1pixantrone 1pertuzumab 1peginterferon alfa-2a 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × atezolizumab × Tumor-Agnostic × Clear all
NCT06762808 2025-08-15

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT06416436 2025-06-29

Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients

University of Kansas Medical Center

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡